EUVIMEDEUVIMED entdecken
Crossref

Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy

Zhu Chen, You-Teng Qin, Qian-Ru Li, Jin-Lian He, Xin-Chen Deng, Yun Zhang, Hao-Dong Yang, Jun Feng, Yun-Xia Sun, Xian-Zheng Zhang iD

Advanced Materials · 2025-07 · 37 (26)

DOI: 10.1002/adma.202503571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 06.05.2025. Verfasst von Zhu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, 430072, P. R. China. Hauptthemen laut MEDLINE: Immunotherapy, Bifidobacterium, Cancer Vaccines, Peptides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gut‐associated lymphoid tissue (GALT) possesses a highly specialized immune system and is rational as a foothold for oral tumor vaccines. Here, a noninvasive oral vaccine (Bif‐OVA‐Ocur) is designed to engage GALT, inducing both intestinal mucosal and systemic immunity for tumor therapeutics. The vaccine uses Bifidobacterium (Bif) as a delivery vehicle for tumor antigen peptides, which are coated with antigen peptides (OVA) and oxidized curdlan (Ocur) in a layer‐by‐layer (LBL) manner. Upon oral administration, Bif‐OVA‐Ocur is efficiently directed to Peyer's patches (PPs) in the intestines and further presented to antigen‐presenting cells (APCs), which then migrate to the mesenteric lymph nodes (MLNs) to evoke specific T cell responses. In mouse models, Bif‐OVA‐Ocur effectively boosts the production of secretory immunoglobin A (SIgA) and promotes a strong mucosal and systemic immune response, leading to significant tumor suppression and resistance to tumor challenges. Importantly, the vaccine shows no systemic toxicity. This approach to harnessing the intestinal mucosal immune system offers valuable insights for the development of other non‐invasive oral vaccines and therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyBifidobacteriumCancer VaccinesPeptidesAntigens, NeoplasmLymphatic SystemAnimalsMiceMice, Inbred C57BLOvalbuminAdministration, OralPrecision MedicineHumansCell Line, TumorFemalebeta-Glucans

Stichwörter der Autor:innen

bifidobacteriumcross‐presentationintestinal mucosal immunitymesenteric lymph nodesoral vaccine

Substanzen

Cancer VaccinesPeptidesAntigens, NeoplasmOvalbuminbeta-Glucans

Autor:innen und Institutionen

  • Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, 430072, P. R. China.

ORCID-Profile: Xian-Zheng Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Z., Qin, Y. T., Li, Q. R., He, J. L., Deng, X. C., Zhang, Y., Yang, H. D., Feng, J., Sun, Y. X., & Zhang, X. Z. (2025). Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy. Advanced Materials, 37(26). https://doi.org/10.1002/adma.202503571

Vancouver

Chen Z, Qin YT, Li QR, He JL, Deng XC, Zhang Y, et al. Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy. Advanced Materials. 2025;37(26). doi:10.1002/adma.202503571

BibTeX
@article{Chen2025,
  author = {Chen, Zhu and Qin, You-Teng and Li, Qian-Ru and He, Jin-Lian and Deng, Xin-Chen and Zhang, Yun and Yang, Hao-Dong and Feng, Jun and Sun, Yun-Xia and Zhang, Xian-Zheng},
  title = {Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {26},
  doi = {10.1002/adma.202503571}
}
Kostenlos starten →